Tannaz Armaghany, MD

home / authors / tannaz-armaghany-md

Articles

Dr. Armaghany on the Utility of ctDNA in CRC

Dr. Armaghany on the Utility of ctDNA in CRC

Tannaz Armaghany, MD
June 4th 2020

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Read More

Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCC

Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCC

Tannaz Armaghany, MD
April 4th 2020

Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.

Read More

Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

Tannaz Armaghany, MD
March 26th 2020

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Read More

Dr. Armaghany on Gene Sequencing in CRC

Dr. Armaghany on Gene Sequencing in CRC

Tannaz Armaghany, MD
March 13th 2020

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data